Summary

This article presents an analysis from the Anglo-Scandinavian Cardiac Outcomes [ASCOT] Trial database, showing that screening for high-sensitivity C-reactive protein (hsCRP) only minimally improved risk assessment in middle-aged patients with traditional cardiovascular disease risk factors.